Select therapeutic use:
Indications for PROHANCE:
For use in MRI in adults and children ≥2 years of age to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. For use in MRI in adults to visualize lesions in the head and neck.
Give as rapid IV infusion (10–60mL/min) or bolus (>60mL/min). CNS: 0.2mL/kg; a second dose of 0.4mL/kg may be given up to 30 minutes after the first in patients suspected of having poorly enhancing lesions. Extracranial/extraspinal tissues: 0.2mL/kg.
<2yrs: not recommended. ≥2yrs: CNS: 0.2mL/kg.
Chronic, severe kidney disease (GFR<30mL/min/1.73m2), acute kidney injury: increased risk of nephrogenic systemic fibrosis; avoid unless necessary, allow sufficient period of time for elimination prior to re-administration. Screen for acute kidney injury and other conditions that reduce renal function (eg, >60yrs, hypertension, diabetes). Sickle cell anemia and other hemoglobinopathies. Renal or hepatic failure. Seizure disorder. History of asthma/allergic disorders. Anaphylactoid reaction possible (may be fatal); have emergency resuscitative equipment available. Avoid extravasation. Pregnancy (Cat.C). Nursing mothers.
Gadolinium-based contrast agent.
Nausea, taste perversion.
Single-dose vials (5mL, 10mL, 15mL, 20mL)—5; Prefilled syringe (10mL, 17mL)—5